ImmunoCellular Therapeutics Ltd. is a biotechnology company focused on the development of novel immune-based cancer therapies. Data from the company’s recent clinical trial of ICT-107, the company’s dendritic cell-based cancer vaccine candidate, will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) June 4-8 in Chicago.
“Immune response correlation with progression-free survival in glioblastoma (GBM) following dendritic cell immunotherapy (ICT-107)” will feature data showing ICT-107’s efficiency in significantly increasing survival rates in patients who received the vaccine.
The company’s phase I clinical included the study of ICT-107 in newly diagnosed patients who received the vaccine along with the standard of care of surgery, radiation and chemotherapy. The results show a one-year overall survival of 100 percent and a two year survival of 80 percent, a significant increase from historical rates of 61.1 percent for one-year and 26.5 percent for two-year survival based on the standard of care alone.
Surasak Phuphanich, M.D., director of the Neuro-Oncology Program at Cedars-Sinai Medical Center, noted that treatment for GBM is thin, and that ImmunoCellular will continue to move forward with additional research.
“These new data further establish ICT-107 as a promising potential treatment for glioblastoma, a disease for which there are currently few and limited treatment options,” Phuphanich stated in the press release. “We are excited for what these data mean for patients, the medical community, and the field of immunotherapy as a whole. We look forward to further investigating ICT-107 in additional clinical studies.”
The company also reported that safety data for ICT-107 fared well compared to current treatments and that no serious adverse events were reported; minor side effects were limited to fatigue, skin rash and pruritis.
For more information on the company, visit www.imuc.com
Let us hear your thoughts below: